Personalized Antisense Oligonucleotide Therapy for a Participant With TARDBP ALS

NCT07703462 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

ENROLLING_BY_INVITATION

Status

1

Enrollment

OTHER

Sponsor class

Conditions

Amyotrophic Lateral Sclerosis (ALS)

Interventions

DRUG: nL-TARDB-002

Sponsor

n-Lorem Foundation

Collaborators

[object Object]